AstraZeneca announced that it will begin using artificial intelligence in its drug discovery and development efforts through a new partnership with London-based health tech company BenevolentAI.
With AstraZeneca's collection of genomics, chemistry and clinical data and BenevolentAI's own scientific data and target-identifying software, scientists from both organizations will use AI and machine learning programs to find connections among biomedical data. Those findings will help scientists understand the root causes of diseases and thus pinpoint potential drug targets.
The partnership will specifically focus on finding and developing new treatments for chronic kidney disease and idiopathic pulmonary fibrosis, both of which have complex underlying biology and will require intensive analysis in order to be better understood and effectively treated.
More articles about AI:
AI-powered smartphone scanner diagnoses diabetic retinopathy on the spot
Y Combinator accelerator will prioritize biotech startups using AI for drug discovery
MIT report calls for the study of 'machine behavior' as technology advances